Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix™ is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development

Hung, Chien-Fu

Monie, Archana

Roden, Richard

Wu, T-C

English

PubMed

Archana Monie1, Chien-Fu Hung1,2, Richard Roden1,2,4, T-C Wu1,2,3,41Departments of Pathology, 2Obstetrics and Gynecology, 3Molecular Microbiology and Immunology, and 4Oncology, 5Institute of Genetic Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USAAbstract: Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix&amp;trade; is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development.Keywords: HPV, L1, VLP, vaccine, Cervari

Archana Monie

Chien-Fu Hung

Richard Roden

T-C Wu

Directory of Open Access Journals

Biologics Targets and Therapy

Cervarix&amp;trade;: a vaccine for the prevention of HPV 16, 18-associated cervical cancer

A controlled trial of a human papillomavirus type 16 vaccine.

A Phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

A phase I study to evaluate a human papillomavirus (HPV)

Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Classiﬁ cation of papillomaviruses.

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.

Early assessment of the efﬁ cacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

Efﬁ cacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Efﬁ cacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly.

Global cancer statistics.

Heterogeneity of the human papillomavirus group.

High sustained efﬁ cacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

How will HPV vaccines affect cervical cancer? Nat Rev Cancer,

HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions.

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-speciﬁ c antibodies in human sera.

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles.

Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun,

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.

Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge.

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 viruslike particle vaccine containing AS04 adjuvant.

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.

Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.

Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium. Infect Immun,

Immunologic responses following administration of a vaccine targeting human papillomavirus

Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.

Induction of type-speciﬁ c neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology,

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Opportunities to improve the prevention and treatment of cervical cancer. Curr Mol Med,

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Papillomaviruses and cancer: from basic studies to clinical application.

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of HPV16 minor capsid antigen L2.

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of l2, the minor capsid protein.

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins.

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell,

Substantial impact on precancerous lesions and HPV infections through 5.5 years

Sustained efﬁ cacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in ﬁ ssion yeast Schizosaccharomyces pombe.

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2727782

Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer

Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals